Biodexa Pharmaceuticals BDRX Income Statement (2013-2025)

NASDAQ BDRX
$0.81 -0.02 (-2.24%)
At close: Sep 9, 2026 · 4:00 PM EDT
Reported Financials

Biodexa Pharmaceuticals Quarterly Income Statement

Periods 26 quarters
Latest Dec 2025

Biodexa Pharmaceuticals income statement data for the quarter ended Dec 2025. This income statement covers 26 quarters of results from Dec 2013 through Dec 2025, standardized by Business Quant from the company’s SEC filings.

Income Statement Dec2013 Dec2014 Dec2015 Jun2016 Dec2016 Jun2017 Dec2017 Jun2018 Dec2018 Jun2019 Dec2019 Jun2020 Sep2020 Dec2020 Jun2021 Sep2021 Dec2021 Jun2022 Sep2022 Dec2022 Jun2023 Dec2023 Jun2024 Dec2024 Jun2025 Dec2025
Revenue & Cost
Provisions
0.21M0.12M0.07M0.07M0.05M0.24M0.10M
Revenue
8.77M5.00M0.58M0.21M0.22M
Interest income
Interest Income - Deposits
0.00M0.00M0.01M0.01M
Interest expenses
Interest ExpensesInterest Expense
-0.08M-0.76M-0.12M-0.03M-0.57M-0.22M-0.21M-0.03M-0.06M-0.03M-0.05M-0.06M-0.18M
Interest Income - Net
-0.01M-0.03M-0.03M-0.02M-0.01M-0.01M-0.01M
Non-interest income
Income - Equity
-1.81M19.58M
Asset Management
0.13M
Investment Advisory
Non-Interest Income
0.13M-1.81M19.58M
Operating Items
Depreciation & Amortization - TotalDep. & Amort. (Tot)
1.31M0.16M0.12M
Research & DevelopmentR&D
-12.04M-10.08M-5.02M-8.01M-2.79M-6.27M-2.98M-5.99M-2.82M-5.05M-2.81M-2.22M
Restructuring CostsRestructuring
-5.65M-4.94M-3.68M-6.55M-2.27M-3.97M-2.29M-5.33M-2.87M-5.39M-2.61M-3.17M
Other Operating ExpensesOther Opex
-0.06M0.00M
Operating ExpensesOpex
1.31M-17.70M-15.02M-8.71M-14.56M-5.07M-10.09M-5.15M-11.32M-5.68M-10.44M-5.42M-5.39M
Operating IncomeOp. Inc
-8.83M-15.20M-14.55M-23.10M-30.42M-4.49M-9.43M-4.67M-10.48M-5.31M-9.95M-5.42M-5.36M
EBIT
-8.83M-15.20M-14.55M-23.10M-30.42M-4.49M-9.43M-4.67M-10.48M-5.31M-9.95M-5.42M-5.36M
Non-operating items
Non Operating Interest Expenses
-0.08M-0.76M-0.12M-0.03M-0.57M-0.22M-0.21M-0.03M-0.06M-0.03M-0.05M-0.06M-0.18M
Interest & Investment IncomeInt & Inv Inc
0.00M0.64M0.67M0.50M-1.53M1.08M
Other Non Operating IncomeOther Non Op Inc.
-0.05M-0.00M
Net income details
EBT
-8.76M-15.96M-14.04M-22.49M-30.99M-4.71M-8.23M-4.20M-9.96M-4.83M-9.29M-4.41M-5.30M
Tax ProvisionsTaxes
1.07M0.55M0.58M0.33M0.32M0.42M0.19M0.16M
Profit After TaxPAT
-15.54M-22.80M-13.23M-21.76M-28.63M-4.38M-7.36M-3.79M-8.98M8.93M-8.79M-4.25M10.15M
Income from Non-Controlling InterestsInc. Minority
0.69M-3.46M-0.27M0.19M
Income from Continuing OperationsIncome (Continuing)
-8.76M-15.96M-15.11M-23.04M-31.57M-5.04M-8.55M-4.62M-10.14M-4.83M-9.29M-4.57M-5.30M
Income from Discontinued OperationsIncome (Discontinued)
-5.79M-6.00M-1.22M
Consolidated Net IncomeConsol Net Inc.
-14.54M-21.95M-16.33M-23.04M-31.57M-5.04M-8.55M-4.62M-10.14M-4.83M-9.29M-4.57M-5.30M
Income towards Parent CompanyParent Net Inc
-14.54M-19.34M-12.97M-21.94M-29.30M-4.38M-7.36M-3.79M-8.98M-4.46M-8.79M-4.25M-5.08M
Preferred Dividend PaymentsPref Dividends
-0.10M-0.00M-0.00M-0.01M-1.04M
Net Income towards Common StockholdersNet Income
-14.54M-19.34M-12.97M-21.94M-29.20M-4.38M-7.36M-3.79M-8.98M-4.46M-8.78M-3.21M-5.08M
Additional items
EPS (Basic)
-40.32-53.61-14.15-23.93-68.16-10.23-9.13-4.70-9.08-4.52-8.88-3.25-5.14
Shares Outstanding
0.36M0.36M0.36M0.36M0.92M0.92M0.92M0.43M0.43M0.43M0.81M0.81M0.81M0.99M0.99M0.99M0.99M0.99M0.99M0.99M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
0.92M0.43M0.81M1.08M
EBITDA
-7.53M-15.20M-14.55M-23.10M-30.42M-4.49M-9.28M-4.55M-10.48M-5.31M-9.95M-5.42M-5.36M